Treatment of Atrial Fibrillation

AHRQ: June 4, 2013

Objectives. There are two generally accepted strategies for managing atrial fibrillation (AF): rate control and rhythm control. However, within each strategic approach there are a large number of potential pharmacological and nonpharmacological therapies, and the comparative safety and effectiveness of these therapies—both within and between strategies—are uncertain.

Data sources. We searched PubMed®, Embase®, and the Cochrane Database of Systematic Reviews for relevant English-language comparative studies.

Review methods. Two investigators screened each abstract and full-text article for inclusion, abstracted data, rated quality and applicability, and graded evidence. When possible, random- effects models were used to compute summary estimates of effects.

Results. Our review included 182 articles (148 unique studies): 14 studies relevant to rate- control drugs, 3 relevant to strict versus lenient rate control, 6 relevant to rate-control procedures versus drugs in patients for whom initial pharmacotherapy was ineffective, 42 relevant to antiarrhythmic drugs and electrical cardioversion for conversion to sinus rhythm, 83 relevant to rhythm-control procedures and drugs for maintenance of sinus rhythm, and 14 focusing on the comparison of rate- and rhythm-control strategies.    Read more

National Minority Quality Forum
Clinical Trial Engagement Network Map Childhood Obesity MapHIV Z-Atlas: Peripheral Arterial Disease Atlas Map Lung Cancer Index Z-Atlas: Chronic Kidney Disease AFIB Index Cardiometabolic Health Aliance Minority Diabetes Coalition U.S. Diabetes Index County Edition U.S. Diabetes Index Research Edition Medicare Index Medicare Index Stroke Edition About The Minority Stroke Working Group Hepatitis C Disease Index Lead Risk Index Map MRSA StrokePAD Minority Index The South Texas Diabetes Initiative Minority Stroke Consortium YouTube NMQF Videos IPAB Action Center National Health Index

© 2011 National Minority Quality Forum, Inc. All Rights Reserved.